Khaled Alrosan

Dr. Khaled Alrosan

Clinical pharmacy and pharmaceutical practice, Hashemite University, Zarqa, Jordan
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
AAAbdelrahim Alqudah
Abdelrahim Alqudah
EQEsam Qnais
Esam Qnais
MWMohammed Wedyan
Mohammed Wedyan
SASara Qasem Altaber
Sara Qasem Altaber
YBYousra Bseiso
Yousra Bseiso
OGOmar Gammoh
Omar Gammoh
Background: Isorhamnetin is a flavonoid that is found in medical plants. Several studies showed that isorhamnetin has anti-inflammatory and anti-obesity effects. This study aims to investigate the anti-diabetic effects of isorhamnetin in a high-fat diet and Streptozotocin-(HFD/STZ)-induced mice model of type 2 diabetes. Materials and Methods: Mice were fed with HFD followed by two consecutive low doses of STZ (40 mg/kg). HFD/STZ diabetic mice were treated orally with isorhamnetin (10 mg/kg) or (200 mg/kg) metformin for 10 days before sacrificing the mice and collecting plasma and soleus muscle for further analysis. Results: Isorhamnetin reduced the elevated levels of serum glucose compared to the vehicle control group (p < 0.001). Isorhamnetin abrogated the increase in serum insulin in the treated diabetic group compared to the vehicle control mice (p < 0.001). The homeostasis model assessment of insulin resistance (HOMA-IR) was decreased in diabetic mice treated with isorhamnetin compared to the vehicle controls. Fasting glucose level was significantly lower in diabetic mice treated with isorhamnetin during the intraperitoneal glucose tolerance test (IPGTT) (p < 0.001). The skeletal muscle protein contents of GLUT4 and p-AMPK-α were upregulated following treatment with isorhamnetin (p > 0.01). LDL, triglyceride, and cholesterol were reduced in diabetic mice treated with isorhamnetin compared to vehicle control (p < 0.001). Isorhamnetin reduced MDA, and IL-6 levels (p < 0.001), increased GSH levels (p < 0.001), and reduced GSSG levels (p < 0.05) in diabetic mice compared to vehicle control. Conclusions: Isorhamnetin ameliorates insulin resistance, oxidative stress, and inflammation. Isorhamnetin could represent a promising therapeutic agent to treat T2D.

3 June 2025 in Oncology Letters
Verified
Journal Article
Open access
PDF file
KAKhaled Alrosan
Khaled Alrosan
AAAmjad Z. Alrosan
Amjad Z. Alrosan
GHGhaith B. Heilat
Ghaith B. Heilat
AAAlaa F. Alrousan
Alaa F. Alrousan
OGOmar S. Gammoh
Omar S. Gammoh
MAMohammed J. Alrousan
Mohammed J. Alrousan
Ovarian cancer is the most lethal malignancy among female genital cancers, primarily due to the non‑specific symptoms, late‑stage diagnosis and poor prognosis. Thus, there is a need for accurate and precise diagnostic methods to improve overall survival rates. The aim of the present review was to provide a comprehensive overview of ovarian cancer, including its epidemiology, clinical presentation, etiology, risk factors, staging and diagnostic techniques, in addition to examining the therapeutic approaches, including cytoreductive surgery and adjuvant treatments, while highlighting the mechanisms of resistance to such interventions. Advancements in molecular profiling and a deeper understanding of ovarian tumorigenesis have led to the introduction of novel therapeutic agents currently in clinical use or under clinical investigation. These innovations may improve the management of ovarian cancer, potentially improving survival outcomes.

1 March 2023 in Heliyon
Verified
Journal Article
Open access
OGOmar Salem Gammoh
Omar Salem Gammoh
EQEsam Qnais
Esam Qnais
YBYousra Bseiso
Yousra Bseiso
KAKhaled Alrosan
Khaled Alrosan
AAAbdelrahim Alqudah
Abdelrahim Alqudah
Pain is a common undertreated worldwide complaint. The need to explore the antinociceptive potential of alternative herbal products is essential. Although used as a mild sedative, limited evidence focused on the potential antinociceptive effect of valerian and hops combination. The present study was carried out to evaluate the in vivo anti-nociceptive effect of the valerian-hops combination to justify its use as an effective and safe analgesic agent. Anti-nociceptive effects of valerian-hops combination (50, 100, and 200 mg/kg) were assessed in swiss albino mice for performing the acetic acid-induced writhing test, the paw licking test using formalin, the paw licking test using glutamate, and the tail immersion test. The effects were compared to those of diclofenac or morphine in the presence or absence of the opioid receptor antagonist naloxone. Valerian-hops" extract of 100 and 200 mg/kg demonstrated a significant reduction in the number of writhing episodes induced by acetic acid compared to the control (p < 0.05), a significant reduction in the licking number at doses of 100 and 200 mg/kg in the late phase formalin-induced paw licking, significantly reduced the number of lickings after glutamate injection compared to control (p < 0.05). And significantly increased pain reaction after 60 and 90 min of tail immersion test, this effect was opposed by naloxone treatment. The valerian-hops combination produced a significant antinociceptive effect that involved the opioid system. Further studies are required to fully uncover the underlying active constituents and their mechanisms.

28 May 2025 in Future Science OA
Verified
Journal Article
Open access
AAAmjad Z. Alrosan
Amjad Z. Alrosan
TATahani Alwidyan
Tahani Alwidyan
GHGhaith B. Heilat
Ghaith B. Heilat
ARAseel O. Rataan
Aseel O. Rataan
SMSaba Madae’eN
Saba Madae’eN
TATasneem Ali
Tasneem Ali
Breast cancer (BC) remains the most common cancer among women worldwide. Early detection plays a vital role in reducing morbidity and mortality. This study aimed to assess Jordanian women's awareness of BC signs and symptoms to support timely recognition and intervention. A nationwide cross-sectional study was conducted involving 381 Jordanian women from the general community. Participants completed a self-administered questionnaire assessing their knowledge of BC signs and symptoms using a three-point Likert scale ("Yes," "Unsure," "No"). Demographic variables were analyzed for association with knowledge levels using Pearson's Chi-square or Fisher's Exact Test. 80.3% of participants demonstrated good awareness of BC signs and symptoms. Significant associations were found between knowledge levels and marital status (p = 0.000), age (p = 0.033), having children (p = 0.000), number of children (p = 0.003), education specialty (p = 0.000), and working area (p = 0.005). Most participants demonstrated a strong awareness of BC signs and symptoms. However, educational interventions are needed to target knowledge gaps, particularly among unmarried women.

28 August 2026 in Next Research
Verified
Journal Article
Open access
KAKhaled Alrosan
Khaled Alrosan
AAAli Alsuraifi
Ali Alsuraifi
Clare HoskinsClare Hoskins
Clare Hoskins
Alan RichardsonAlan Richardson
Alan Richardson

31 July 2025 in Future Science OA
Verified
Journal Article
Open access
KAKhaled Alrosan
Khaled Alrosan
MOMohanad Odeh
Mohanad Odeh
TATahani Alwidyan
Tahani Alwidyan
AAAmjad Z Alrosan
Amjad Z Alrosan
SMSaba Madae’eN
Saba Madae’eN
BackgroundOvarian cancer is the most lethal gynecological cancer in women, which is characterized by nonspecific symptoms that delays its diagnosis until advanced stages, thus it has been called the silent killer disease. Since community pharmacists are easily accessible healthcare providers, and because of their roles in health promotion activities and disease prevention services; this study was conducted to better understand their knowledge, attitudes, and challenges toward ovarian cancer health promotion. An internet-based self-administrated questionnaire was distributed to community pharmacists in Jordan (n = 194) with a response rate of 53.9% through an online platform. About 75.2% of the community pharmacists had insufficient knowledge score of ovarian cancer and 58.2% had a higher-positive attitude. There was a significant association between the community pharmacist knowledge score and the work status or the education level (p < 0.05). The perceived lack of pharmacist' s knowledge and the absence of a private area in pharmacies for confidential conversations represent the major barriers (72.1% and 69.6%, respectively). Despite limited knowledge about the symptoms and risk factors of ovarian cancer, as well as barriers hindering the full realization of community pharmacists' roles, they demonstrated a positive attitude toward educating patients about ovarian cancer health.